4.5 Article

NCCN Guidelines® Insights Palliative Care, Version 2.2017 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0132

关键词

-

类别

资金

  1. Astellas
  2. AstraZeneca
  3. Celldex Therapeutics
  4. Clovis Oncology
  5. Genomic Health, Inc.
  6. Kyowa Hakko Kirin
  7. Jazz Pharmaceuticals
  8. Novartis Pharmaceuticals Corporation
  9. NOVOCURE
  10. Merck Co., Inc.

向作者/读者索取更多资源

The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. These NCCN Guidelines Insights summarize and provide context for the updated guidelines recommendations regarding hospice and end-of-life (EOL) care. Updates for 2017 include revisions to and restructuring of the algorithms that address important EOL concerns. These recommendations were revised to provide clearer guidance for oncologists as they care for patients with cancer who are approaching the transition to EOL care. Recommendations for interventions and reassessment based on estimated life expectancy were streamlined and reprioritized to promote hospice referrals and improved EOL care.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据